Kilian Wistuba-Hamprecht

13PUBLICATIONS
50CO-AUTHORS
Molecular targetsTumour immunologyPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jan 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Robin Reschke, Petra Budde, Hans-Dieter Zucht

|Jan 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Nicola Herold, Jonas Bochem, Johanna Leyens

|May 11, 2024
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.

Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel

|Jan 29, 2024
High-dimensional in situ proteomics imaging to assess γδ T cells in spatial biology.

Nicola Herold, Matthias Bruhns, Sepideh Babaei

|Jul 20, 2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

Markus Haake, Beatrice Haack, Tina Schäfer

|May 14, 2022
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.

Simone Wendlinger, Jonas Wohlfarth, Sophia Kreft

Pageof 3

Frequent Collaborators

5 joint publications

Graham Pawelec

3 joint publications

Matthias Goebeler

2 joint publications

Friedegund Meier

2 joint publications

Nikolaus Benjamin Wagner